{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T22:20:40Z","timestamp":1795126840867,"version":"4.10.3"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Blood phosphorylated (p)-tau 181 and p-tau 217 have been proposed as accurate biomarkers of Alzheimer\u2019s disease (AD) pathology. However, blood p-tau 181 is also elevated in amyotrophic lateral sclerosis (ALS) without a clearly identified source. We measured serum p-tau 181 and p-tau 217 in a multicentre cohort of ALS (n\u2009=\u2009152), AD (n\u2009=\u2009111) cases and disease controls (n\u2009=\u200999) recruited from four different centres. Further, we investigated the existence of both p-tau species using immunohistochemistry (IHC) and mass spectrometry (MS)\u00a0in muscle biopsies of ALS cases (IHC: n\u2009=\u200913, MS: n\u2009=\u20095) and disease controls (IHC: n\u2009=\u200914, MS: n\u2009=\u20095) from one cohort. Serum p-tau 181 and p-tau 217 were higher in AD and ALS patients compared to disease controls. IHC and MS analyses revealed the presence of p-tau 181 and 217 in muscle biopsies from both ALS cases and disease controls, with ALS samples showing increased p-tau reactivity in atrophic muscle fibres. Blood p-tau species could potentially be used to diagnose both ALS and AD.<\/jats:p>","DOI":"10.1038\/s41467-025-57144-7","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T10:04:38Z","timestamp":1741169078000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":92,"title":["Phosphorylated tau 181 and 217 are elevated in serum and muscle of patients with amyotrophic lateral sclerosis"],"prefix":"10.1038","volume":"16","author":[{"given":"Samir","family":"Abu-Rumeileh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Scholle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0089-4473","authenticated-orcid":false,"given":"Alexander","family":"Mensch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5122-2477","authenticated-orcid":false,"given":"Henning","family":"Gro\u00dfkopf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4264-6614","authenticated-orcid":false,"given":"Antonia","family":"Ratti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"K\u00f6lsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gisela","family":"Stoltenburg-Didinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Conrad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"De Gobbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Barba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Steinacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8672-9032","authenticated-orcid":false,"given":"Hans-Wolfgang","family":"Klafki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7652-7023","authenticated-orcid":false,"given":"Patrick","family":"Oeckl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8711-5702","authenticated-orcid":false,"given":"Steffen","family":"Halbgebauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Stapf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Posa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Kendzierski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7698-3854","authenticated-orcid":false,"given":"Vincenzo","family":"Silani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9009-2356","authenticated-orcid":false,"given":"Lucrezia","family":"Hausner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5963-7426","authenticated-orcid":false,"given":"Nicola","family":"Ticozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1494-0813","authenticated-orcid":false,"given":"Lutz","family":"Froelich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen Hans","family":"Weishaupt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Verde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4273-4267","authenticated-orcid":false,"given":"Markus","family":"Otto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,5]]},"reference":[{"key":"57144_CR1","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack","year":"2018","unstructured":"Jack, C. R. et al. NIA-AA Research Framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 14, 535\u2013562 (2018).","journal-title":"Alzheimers Dement."},{"key":"57144_CR2","doi-asserted-by":"publisher","unstructured":"Jack, C. R. et al. Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup. Alzheimers Dement. https:\/\/doi.org\/10.1002\/alz.13859 (2024).","DOI":"10.1002\/alz.13859"},{"key":"57144_CR3","doi-asserted-by":"publisher","unstructured":"Barba, L. et al. Clinical and diagnostic implications of Alzheimer\u2019s disease copathology in Lewy body disease. Brain. https:\/\/doi.org\/10.1093\/brain\/awae203 (2024).","DOI":"10.1093\/brain\/awae203"},{"key":"57144_CR4","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","volume":"19","author":"TK Karikari","year":"2020","unstructured":"Karikari, T. K. et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer\u2019s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 19, 422\u2013433 (2020).","journal-title":"Lancet Neurol."},{"key":"57144_CR5","doi-asserted-by":"publisher","first-page":"4967","DOI":"10.1002\/alz.13026","volume":"19","author":"J Therriault","year":"2023","unstructured":"Therriault, J. et al. Equivalence of plasma p-tau217 with cerebrospinal fluid in the diagnosis of Alzheimer\u2019s disease. Alzheimers Dement. 19, 4967\u20134977 (2023).","journal-title":"Alzheimers Dement."},{"key":"57144_CR6","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1001\/jamaneurol.2023.5319","volume":"81","author":"NJ Ashton","year":"2024","unstructured":"Ashton, N. J. et al. Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer disease pathology. JAMA Neurol. 81, 255\u2013263 (2024).","journal-title":"JAMA Neurol."},{"key":"57144_CR7","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1007\/s00415-023-12148-5","volume":"271","author":"AJ Mendes","year":"2024","unstructured":"Mendes, A. J. et al. Head-to-head study of diagnostic accuracy of plasma and cerebrospinal fluid p-tau217 versus p-tau181 and p-tau231 in a memory clinic cohort. J. Neurol. 271, 2053\u20132066 (2024).","journal-title":"J. Neurol."},{"key":"57144_CR8","doi-asserted-by":"publisher","first-page":"3546","DOI":"10.1093\/brain\/awac175","volume":"145","author":"MS Morrison","year":"2022","unstructured":"Morrison, M. S. et al. Ante-mortem plasma phosphorylated tau (181) predicts Alzheimer\u2019s disease neuropathology and regional tau at autopsy. Brain 145, 3546\u20133557 (2022).","journal-title":"Brain"},{"key":"57144_CR9","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1002\/ana.26462","volume":"92","author":"KAQ Cousins","year":"2022","unstructured":"Cousins, K. A. Q. et al. Elevated plasma phosphorylated Tau 181 in amyotrophic lateral sclerosis. Ann. Neurol. 92, 807\u2013818 (2022).","journal-title":"Ann. Neurol."},{"key":"57144_CR10","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1136\/jnnp-2022-330709","volume":"94","author":"V Vacchiano","year":"2023","unstructured":"Vacchiano, V. et al. Elevated plasma p-tau181 levels unrelated to Alzheimer\u2019s disease pathology in amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry 94, 428\u2013435 (2023).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"57144_CR11","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.3233\/JAD-230900","volume":"95","author":"L Barba","year":"2023","unstructured":"Barba, L., Otto, M. & Abu-Rumeileh, S. The underestimated relevance of Alzheimer\u2019s disease copathology in amyotrophic lateral sclerosis. J. Alzheimers Dis. 95, 1401\u20131404 (2023).","journal-title":"J. Alzheimers Dis."},{"key":"57144_CR12","doi-asserted-by":"publisher","first-page":"3697","DOI":"10.1007\/s10072-023-06916-4","volume":"44","author":"F Verde","year":"2023","unstructured":"Verde, F. et al. Phosphorylated tau in plasma could be a biomarker of lower motor neuron impairment in amyotrophic lateral sclerosis. Neurol. Sci. 44, 3697\u20133702 (2023).","journal-title":"Neurol. Sci."},{"key":"57144_CR13","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1002\/cm.21812","volume":"81","author":"M Goedert","year":"2024","unstructured":"Goedert, M., Crowther, R. A., Scheres, S. H. W. & Spillantini, M. G. Tau and neurodegeneration. Cytoskeleton 81, 95\u2013102 (2024).","journal-title":"Cytoskeleton"},{"key":"57144_CR14","doi-asserted-by":"crossref","unstructured":"Ceccanti, M. et al. Creatine kinase and progression rate in amyotrophic lateral sclerosis. Cells 9, 1174 (2020).","DOI":"10.3390\/cells9051174"},{"key":"57144_CR15","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcab274","volume":"3","author":"S Castro-Gomez","year":"2021","unstructured":"Castro-Gomez, S. et al. Teaching an old dog new tricks: serum troponin T as a biomarker in amyotrophic lateral sclerosis. Brain Commun. 3, fcab274 (2021).","journal-title":"Brain Commun."},{"key":"57144_CR16","doi-asserted-by":"crossref","unstructured":"Vidovic, M. et al. Comparative analysis of neurofilaments and biomarkers of muscular damage in amyotrophic lateral sclerosis. Brain Commun. 6, fcae288 (2024).","DOI":"10.1093\/braincomms\/fcae288"},{"key":"57144_CR17","doi-asserted-by":"crossref","unstructured":"Barth\u00e9lemy, N. R., Horie, K., Sato, C. & Bateman, R. J. Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer\u2019s disease. J. Exp. Med. 217, e20200861 (2020).","DOI":"10.1084\/jem.20200861"},{"key":"57144_CR18","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1093\/brain\/awac407","volume":"146","author":"F Gonzalez-Ortiz","year":"2023","unstructured":"Gonzalez-Ortiz, F. et al. Brain-derived tau: a novel blood-based biomarker for Alzheimer\u2019s disease-type neurodegeneration. Brain 146, 1152\u20131165 (2023).","journal-title":"Brain"},{"key":"57144_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05767-7","volume":"22","author":"E Agah","year":"2024","unstructured":"Agah, E. et al. CSF and blood levels of Neurofilaments, T-Tau, P-Tau, and Abeta-42 in amyotrophic lateral sclerosis: a systematic review and meta-analysis. J. Transl. Med. 22, 953 (2024).","journal-title":"J. Transl. Med."},{"key":"57144_CR20","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1002\/acn3.50943","volume":"6","author":"T Kasai","year":"2019","unstructured":"Kasai, T. et al. Combined use of CSF NfL and CSF TDP\u201043 improves diagnostic performance in ALS. Ann. Clin. Transl. Neurol. 6, 2489\u20132502 (2019).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"57144_CR21","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1021\/acschemneuro.2c00636","volume":"14","author":"M Ni","year":"2023","unstructured":"Ni, M. et al. Plasma core Alzheimer\u2019s disease biomarkers predict amyloid deposition burden by positron emission tomography in chinese individuals with cognitive decline. ACS Chem. Neurosci. 14, 170\u2013179 (2023).","journal-title":"ACS Chem. Neurosci."},{"key":"57144_CR22","doi-asserted-by":"publisher","unstructured":"Bentivenga, G. M. et al. Clinical value of novel blood\u2010based tau biomarkers in Creutzfeldt\u2013Jakob disease. Alzheimer\u2019s Dementia. https:\/\/doi.org\/10.1002\/alz.14422 (2024).","DOI":"10.1002\/alz.14422"},{"key":"57144_CR23","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1111\/j.1365-2990.2004.00577.x","volume":"30","author":"C-A Maurage","year":"2004","unstructured":"Maurage, C.-A. et al. Tau aggregates are abnormally phosphorylated in inclusion body myositis and have an immunoelectrophoretic profile distinct from other tauopathies. Neuropathol. Appl Neurobiol. 30, 624\u2013634 (2004).","journal-title":"Neuropathol. Appl Neurobiol."},{"key":"57144_CR24","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s00401-011-0874-3","volume":"122","author":"C D\u2019Agostino","year":"2011","unstructured":"D\u2019Agostino, C., Nogalska, A., Cacciottolo, M., Engel, W. K. & Askanas, V. Abnormalities of NBR1, a novel autophagy-associated protein, in muscle fibers of sporadic inclusion-body myositis. Acta Neuropathol. 122, 627\u2013636 (2011).","journal-title":"Acta Neuropathol."},{"key":"57144_CR25","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3390\/jor1010003","volume":"1","author":"NV Shults","year":"2020","unstructured":"Shults, N. V. et al. Tau protein in lung smooth muscle cells. J. Respir. 1, 30\u201339 (2020).","journal-title":"J. Respir."},{"key":"57144_CR26","doi-asserted-by":"publisher","first-page":"178","DOI":"10.3109\/17482968.2011.622405","volume":"13","author":"W Yang","year":"2012","unstructured":"Yang, W. & Strong, M. J. Widespread neuronal and glial hyperphosphorylated tau deposition in ALS with cognitive impairment. Amyotroph. Lateral Scler. 13, 178\u2013193 (2012).","journal-title":"Amyotroph. Lateral Scler."},{"key":"57144_CR27","doi-asserted-by":"publisher","first-page":"477","DOI":"10.2119\/molmed.2016.00095","volume":"22","author":"CR Vintilescu","year":"2016","unstructured":"Vintilescu, C. R., Afreen, S., Rubino, A. E. & Ferreira, A. The Neurotoxic TAU45-230 fragment accumulates in upper and lower motor neurons in amyotrophic lateral sclerosis subjects. Mol. Med. 22, 477\u2013486 (2016).","journal-title":"Mol. Med."},{"key":"57144_CR28","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1093\/jnen\/nlz041","volume":"78","author":"CH Stevens","year":"2019","unstructured":"Stevens, C. H., Guthrie, N. J., van Roijen, M., Halliday, G. M. & Ooi, L. Increased tau phosphorylation in motor neurons from clinically pure sporadic amyotrophic lateral sclerosis patients. J. Neuropathol. Exp. Neurol. 78, 605\u2013614 (2019).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"57144_CR29","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1093\/brain\/awac161","volume":"145","author":"E Vacchi","year":"2022","unstructured":"Vacchi, E. et al. Tau protein quantification in skin biopsies differentiates tauopathies from alpha-synucleinopathies. Brain 145, 2755\u20132768 (2022).","journal-title":"Brain"},{"key":"57144_CR30","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1093\/brain\/awad381","volume":"147","author":"H Tanaka","year":"2024","unstructured":"Tanaka, H. et al. Distinct involvement of the cranial and spinal nerves in progressive supranuclear palsy. Brain 147, 1399\u20131411 (2024).","journal-title":"Brain"},{"key":"57144_CR31","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1002\/mds.30009","volume":"39","author":"M Rosina","year":"2024","unstructured":"Rosina, M. et al. Immunometabolic signature and tauopathy markers in blood cells of progressive supranuclear palsy. Mov. Disord. 39, 2211\u20132219 (2024).","journal-title":"Mov. Disord."},{"key":"57144_CR32","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1136\/jnnp-2021-327129","volume":"93","author":"S Halbgebauer","year":"2022","unstructured":"Halbgebauer, S. et al. Comparison of CSF and serum neurofilament light and heavy chain as differential diagnostic biomarkers for ALS. J. Neurol. Neurosurg. Psychiatry 93, 68\u201374 (2022).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"57144_CR33","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1080\/21678421.2016.1241279","volume":"18","author":"P Steinacker","year":"2017","unstructured":"Steinacker, P. et al. Diagnostic and prognostic significance of neurofilament light chain NF-L, but not progranulin and S100B, in the course of amyotrophic lateral sclerosis: data from the German MND-net. Amyotroph. Lateral Scler. Frontotemporal Degener. 18, 112\u2013119 (2017).","journal-title":"Amyotroph. Lateral Scler. Frontotemporal Degener."},{"key":"57144_CR34","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1007\/s00415-020-09761-z","volume":"267","author":"S Abu-Rumeileh","year":"2020","unstructured":"Abu-Rumeileh, S. et al. Diagnostic-prognostic value and electrophysiological correlates of CSF biomarkers of neurodegeneration and neuroinflammation in amyotrophic lateral sclerosis. J. Neurol. 267, 1699\u20131708 (2020).","journal-title":"J. Neurol."},{"key":"57144_CR35","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1136\/jnnp-2018-318704","volume":"90","author":"F Verde","year":"2019","unstructured":"Verde, F. et al. Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry 90, 157\u2013164 (2019).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"57144_CR36","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41582-024-00955-x","volume":"20","author":"M Khalil","year":"2024","unstructured":"Khalil, M. et al. Neurofilaments as biomarkers in neurological disorders \u2014 towards clinical application. Nat. Rev. Neurol. 20, 269\u2013287 (2024).","journal-title":"Nat. Rev. Neurol."},{"key":"57144_CR37","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1038\/s41582-024-00961-z","volume":"20","author":"M Benatar","year":"2024","unstructured":"Benatar, M. et al. The Miami Framework for ALS and related neurodegenerative disorders: an integrated view of phenotype and biology. Nat. Rev. Neurol. 20, 364\u2013376 (2024).","journal-title":"Nat. Rev. Neurol."},{"key":"57144_CR38","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1080\/146608200300079536","volume":"1","author":"BR Brooks","year":"2000","unstructured":"Brooks, B. R., Miller, R. G., Swash, M. & Munsat, T. L. & World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 1, 293\u2013299 (2000).","journal-title":"Amyotroph. Lateral Scler. Other Motor Neuron Disord."},{"key":"57144_CR39","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1097\/NEN.0b013e318232a379","volume":"70","author":"H Braak","year":"2011","unstructured":"Braak, H., Thal, D. R., Ghebremedhin, E. & Del Tredici, K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J. Neuropathol. Exp. Neurol. 70, 960\u2013969 (2011).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"57144_CR40","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/nrneurol.2014.184","volume":"10","author":"B Swinnen","year":"2014","unstructured":"Swinnen, B. & Robberecht, W. The phenotypic variability of amyotrophic lateral sclerosis. Nat. Rev. Neurol. 10, 661\u2013670 (2014).","journal-title":"Nat. Rev. Neurol."},{"key":"57144_CR41","doi-asserted-by":"publisher","first-page":"e802","DOI":"10.1212\/WNL.0000000000008869","volume":"94","author":"A Chi\u00f2","year":"2020","unstructured":"Chi\u00f2, A. et al. ALS phenotype is influenced by age, sex, and genetics: a population-based study. Neurology 94, e802\u2013e810 (2020).","journal-title":"Neurology"},{"key":"57144_CR42","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1093\/brain\/awr351","volume":"135","author":"JC Roche","year":"2012","unstructured":"Roche, J. C. et al. A proposed staging system for amyotrophic lateral sclerosis. Brain 135, 847\u2013852 (2012).","journal-title":"Brain"},{"key":"57144_CR43","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3109\/21678421.2013.805784","volume":"15","author":"S Abrahams","year":"2014","unstructured":"Abrahams, S., Newton, J., Niven, E., Foley, J. & Bak, T. H. Screening for cognition and behaviour changes in ALS. Amyotroph. Lateral Scler. Frontotemporal Degener. 15, 9\u201314 (2014).","journal-title":"Amyotroph. Lateral Scler. Frontotemporal Degener."},{"key":"57144_CR44","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1136\/jnnp.2010.235952","volume":"82","author":"A Chi\u00f2","year":"2011","unstructured":"Chi\u00f2, A. et al. Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study. J. Neurol. Neurosurg. Psychiatry 82, 740\u2013746 (2011).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"57144_CR45","doi-asserted-by":"publisher","first-page":"e50","DOI":"10.1212\/WNL.0000000000207371","volume":"101","author":"L Barba","year":"2023","unstructured":"Barba, L. et al. CSF synaptic biomarkers in AT(N)-based subgroups of Lewy body disease. Neurology 101, e50\u2013e62 (2023).","journal-title":"Neurology"},{"key":"57144_CR46","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41596-018-0082-x","volume":"14","author":"CS Hughes","year":"2019","unstructured":"Hughes, C. S. et al. Single-pot, solid-phase-enhanced sample preparation for proteomics experiments. Nat. Protoc. 14, 68\u201385 (2019).","journal-title":"Nat. Protoc."},{"key":"57144_CR47","doi-asserted-by":"publisher","first-page":"620270","DOI":"10.3389\/fimmu.2021.620270","volume":"12","author":"H Gro\u00dfkopf","year":"2021","unstructured":"Gro\u00dfkopf, H., Walter, K., Karkossa, I., von Bergen, M. & Schubert, K. Non-genomic AhR-signaling modulates the immune response in endotoxin-activated macrophages after activation by the environmental stressor BaP. Front. Immunol. 12, 620270 (2021).","journal-title":"Front. Immunol."},{"key":"57144_CR48","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1074\/mcp.M113.031591","volume":"13","author":"J Cox","year":"2014","unstructured":"Cox, J. et al. Accurate proteome-wide label-free quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ. Mol. Cell Proteom. 13, 2513\u20132526 (2014).","journal-title":"Mol. Cell Proteom."},{"key":"57144_CR49","doi-asserted-by":"crossref","unstructured":"UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Res. 47, D506\u2013D515 (2019).","DOI":"10.1093\/nar\/gky1049"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-57144-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-57144-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-57144-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T10:04:43Z","timestamp":1741169083000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-57144-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,5]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["57144"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-57144-7","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,5]]},"assertion":[{"value":"31 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.A.R. received research support from the Medical Faculty of Martin-Luther-University Halle-Wittenberg (Clinician Scientist\u00a0Programm No. CS22\/06), unrelated to the work presented in this paper. A.M. has received advisory board honoraria and speaking fees from Hormosan and Sanofi, all unrelated to the submitted work. J.C. received research support from the German Foundation of Neurology (Deutsche Stiftung Neurologie), the Rolf-Schwiete-Stiftung, and the programme for research and education at LMU Munich (FoeFoLe-LMU), all unrelated to the work presented in the paper. L.B. received research support from the Medical Faculty of Martin-Luther-University Halle-Wittenberg (Junior Clinician Scientist Programm No. JCS24\/02), unrelated to the work presented in this paper. P.O. received research support from the Cure Alzheimer Fund, ALS Association (24-SGP-691, 23-PPG-674-2), ALS Finding a Cure, the Charcot Foundation, the DZNE Innovation-to-Application programme and consulting fees from LifeArc and Fundamental Pharma, unrelated to the work presented in this paper. V.S. received compensation for consulting services and\/or speaking activities from AveXis, Cytokinetics, Italfarmaco, Liquidweb S.r.l., Novartis Pharma AG, Amylyx Pharmaceuticals, Biogen, and Zambon Biotech SA; receives or has received research supports from the Italian Ministry of Health, AriSLA, and E-Rare Joint Transnational Call, all unrelated to the work presented in this paper. V.S. is in the Editorial Board of Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, European Neurology, American Journal of Neurodegenerative Diseases, Frontiers in Neurology, and Exploration of Neuroprotective Therapy. V.S., N.T. and F.V. acknowledge the support of Italian Ministry of Health (Ricerca Corrente\/Ricerca Finalizzata; Hub Life Science-Diagnostica Avanzata (HLS-DA), PNC-E3-2022-23683266, the Italian Ministry of Health within the Complementary National Plan Innovative Health Ecosystem) and the Italian Ministry of Education and Research (\u201cDipartimenti di Eccellenza\u201d Program 2023-2027, Department of Pathophysiology and Transplantation, Universit\u00e0 degli Studi di Milano), unrelated to the work presented in this paper. C.S. received support from the Doris Ruess Stiftung, unrelated to the work presented in this paper. M.O. received research support from the German Federal Ministry of Education and Research (projects: FTLDc 01GI1007A), the EU Moodmarker programme (01EW2008), the ALS Association, the foundation of the state Baden-W\u00fcrttemberg (D.3830), Boehringer Ingelheim Ulm University BioCenter (D.5009), and the Thierry Latran Foundation and EU\u2010MIRIADE and the Roux-programme of the Martin Luther University Halle (Saale); M.O. received consulting fees from Biogen, Axon, Roche, and Grifols; and participates on the Biogen ATLAS trial board, all unrelated to the work presented in this paper; is a speaker of the german FTLD consortium, is involved in an unpaid role with the German Society for CSF Diagnostics and Neurochemistry, and is involved without pay with the Society for CSF Diagnostics and Neurochemistry. M.O., P.O., and S.H. are co-inventors of a patent application for using beta-synuclein measurement in blood. The other authors report no disclosures relevant to the manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2019"}}